ArticleBMC infectious diseases2026
Impact of COVID-19 and earthquake disaster on candidemia in the ICU: mortality and treatment outcomes.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandidemia is a serious bloodstream infection with high mortality, particularly in intensive care unit (ICU) patients. Its epidemiology is influenced by evolving practices, resistance, and extraordinary circumstances such as pandemics and disasters. This study aimed to analyze candidemia epidemiology, risk factors, and outcomes, focusing on the impact of the COVID-19 pandemic and a major earthquake in southern Turkey.
methodsWe retrospectively analyzed 739 adult ICU patients diagnosed with candidemia between 2018 and 2023 at a tertiary referral center in Turkey. Patients were grouped as pre-pandemic, COVID-19, and post-earthquake periods. Clinical characteristics, Candida species distribution, antifungal treatment timing, and mortality rates were compared. Logistic regression was performed to identify independent predictors of 30-day mortality.
resultsThere was a total of 739 documented cases, including 261 (35.32%) during the pre-pandemic period, 305 (41.27%) during the COVID-19 period, and 173 (23.41%) during the earthquake period. The overall 30-day mortality rate was 67.52%. Mortality was significantly higher during the COVID-19 period (78.36%) compared to the pre-pandemic (57.47%) and post-earthquake (63.58%) periods (p < 0.001). Non-albicans Candida species accounted for 70.77% of isolates, with C. parapsilosis being most frequent. Delayed initiation of antifungal therapy (> 48 h) and prolonged indwelling catheter duration were associated with increased mortality. Multivariable analysis identified higher Charlson comorbidity index, Candida score, septic shock, mechanical ventilation, and delayed antifungal therapy as independent predictors of mortality (AUC = 0.765).
conclusionCandidemia in ICU patients is associated with high mortality, particularly under crisis conditions such as the COVID-19 pandemic and earthquake disaster. Early antifungal initiation and prompt catheter removal remain critical to improving outcomes. These findings highlight the need for strengthened infection control strategies and disaster preparedness in a resource-challenged setting. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.